The estimated Net Worth of Richard S Casten is at least $37.3 Thousand dollars as of 20 August 2021. Mr Casten owns over 50,000 units of Baudax Bio Inc stock worth over $37,280 and over the last 4 years he sold BXRX stock worth over $0.
Sign up
Mr A BXRX stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Baudax Bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of BXRX stock worth $25,500 on 20 August 2021.
The largest trade he's ever made was buying 50,000 units of Baudax Bio Inc stock on 20 August 2021 worth over $25,500. On average, Mr trades about 25,000 units every 40 days since 2021. As of 20 August 2021 he still owns at least 200,000 units of Baudax Bio Inc stock.
You can see the complete history of Mr Casten stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Richard S. Casten CPA, M.B.A. biography
Richard S. Casten CPA, M.B.A. is the Chief Financial Officer at Baudax Bio Inc.
How old is Mr A?
Mr A is 47, he's been the Chief Financial Officer of Baudax Bio Inc since . There are 4 older and no younger executives at Baudax Bio Inc. The oldest executive at Baudax Bio Inc is Dr. Geraldine A. Henwood Ph.D., 69, who is the Pres, CEO & Director.
What's Mr A's mailing address?
Richard's mailing address filed with the SEC is C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN,, PA, 19355.
Insiders trading at Baudax Bio Inc
Over the last 5 years, insiders at Baudax Bio Inc have traded over $0 worth of Baudax Bio Inc stock and bought 301,900 units worth $299,893 . The most active insiders traders include Winston J Churchill, Alfred Altomari, and Wayne Weisman. On average, Baudax Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $4,063. The most recent stock trade was executed by Geraldine Henwood on 15 December 2022, trading 1,200 units of BXRX stock currently worth $3,060.
What does Baudax Bio Inc do?
baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.
What does Baudax Bio Inc's logo look like?
Complete history of Mr Casten stock trades at Baudax Bio Inc
Baudax Bio Inc executives and stock owners
Baudax Bio Inc executives and other stock owners filed with the SEC include:
-
Dr. Geraldine A. Henwood Ph.D.,
Pres, CEO & Director -
Jillian Dilmore,
Corp. Sec. -
Dr. Jyrki Mattila M.D., MBA, Ph.D.,
Exec. VP of Bus. Devel. -
Diane Myers,
Sr. VP of Regulatory & Quality -
Dr. Stewart McCallum,
Chief Medical Officer -
Richard S. Casten CPA, M.B.A.,
Chief Financial Officer -
Alfred Altomari,
Director -
Wayne Weisman,
Director -
Winston J Churchill,
Director -
William Ashton,
Director -
Ryan David Lake,
Chief Financial Officer -
Arnold M Baskies,
Director -
Pharma, Inc. Recro,
10% owner -
Geraldine Henwood,
President and CEO -
Richard S Casten,
Chief Financial Officer